期刊
MOLECULAR THERAPY-ONCOLYTICS
卷 11, 期 -, 页码 62-74出版社
CELL PRESS
DOI: 10.1016/j.omto.2018.10.001
关键词
-
资金
- National Cancer Institute (Bethesda, MD, USA) [P30 CA016058]
- Cancer Free Kids Pediatric Cancer Research Alliance
- Research Institute at Nationwide Children's Hospital
- NIH HHS/USA [F31 CA203252/CA/NCI]
- Ohio State University Pelotonia Graduate Fellowship
- Nationwide Children's Hospital Student Research Award
- Alex's Lemonade Stand Pediatric Oncology Student Training Fellowship
Ewing sarcoma is a highly aggressive cancer that promotes the infiltration and activation of pro-tumor M2-like macrophages. Oncolytic virotherapy that selectively infects and destroys cancer cells is a promising option for treating Ewing sarcoma. The effect of tumor macrophages on oncolytic virus therapy, however, is variable among solid tumors and is unknown in Ewing sarcoma. We tested the effects of macrophage reduction using liposomal clodronate (Clodrosome) and trabectedin on the antitumor efficacy of intratumoral oncolytic herpes simplex virus, rRp450, in two Ewing sarcoma xenograft models. Both agents enhanced antitumor efficacy without increasing virus replication. The most profound effects were in A673 with only a transient effect on response rates in TC71. Interestingly, A673 was more dependent than TC71 on macrophages for its tumorigenesis. We found Clodrosome and virus together induced expression of antitumorigenic genes and reduced expression of protumorigenic genes in both the tumor-associated macrophages and the overall tumor stroma. Trabectedin reduced intratumoral natural killer (NK) cells, myeloid-derived suppressor cells, and M2-like macrophages, and prevented their increase following virotherapy. Our data suggest that a combination of trabectedin and oncolytic herpes virotherapy warrants testing in the clinical setting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据